DrugBiological
Relatlimab clinical trials
Also written BMS-986016.
- studies test it
- 54
- open now
- 15
- in phase 3
- 4
- first study started
- 2013
Keep track of what changes. Save the relatlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
54 studies that test it; most in 2019 (9)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 9 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 13
- Phase 2
- 42
- Phase 3
- 4
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 15
Who runs them
Industry 19 · Other 35
Bristol-Myers Squibb (19) · National Cancer Institute (NCI) (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · M.D. Anderson Cancer Center (5) · Dan Zandberg (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · The Netherlands Cancer Institute (1) · Melanoma Institute Australia (1)
Often tested with
Tested in the same studies.
Nivolumab (34) · Ipilimumab (14) · Linrodostat (3) · Dasatinib (2) · Sunitinib (2) · Nivolumab, relatlimab drug combination (2) · Rucaparib (2) · Pembrolizumab (2)
Studies
Open first, then newest update. How each study uses relatlimab is read from its arms, and is right about nine times in ten.
Testing it · 54
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386Written as Relatlimab
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruitingPhase 2/3National Cancer Institute (NCI)NCT05987241Written as Relatlimab
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270Written as Relatlimab
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Relatlimab
- Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabRecruitingPhase 2Duke UniversityNCT06816927Written as Relatlimab
- Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06683755Written as Relatlimab
- A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruitingPhase 4Bristol-Myers SquibbNCT07459543Written as Nivolumab + Relatlimab
- Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaRecruitingPhase 2University of California, San DiegoNCT06624475Written as Relatlimab plus Nivolumab
- Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05704647Written as Relatlimab
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingPhase 1Carlo ContrerasNCT04697576Written as Nivolumab + Relatlimab
- Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesRecruitingPhase 2Stanford UniversityNCT06712927Written as Nivolumab + Relatlimab FDC
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03521830Written as Relatlimab
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06295159Written as Nivolumab + Relatlimab
- Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinRecruitingPhase 2Salzburger LandesklinikenNCT04204837Written as Nivolumab plus Relatlimab
- Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLRecruitingPhase 2Ludwig-Maximilians - University of MunichNCT04913922Written as Relatlimab
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Relatlimab
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedPhase 2National Cancer Institute (NCI)NCT06325683Written as Relatlimab
- A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerCompletedPhase 1/2Bristol-Myers SquibbNCT05337137Written as Relatlimab
- Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03607890Written as Relatlimab
- Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05347212Written as Relatlimab
See all 54 studies that test relatlimab →
Given in every arm · 16 — relatlimab is usual care beside what is tested
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Written as Nivolumab + Relatlimab FDC
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingPhase 1ExelixisNCT05176483Written as Nivolumab + Relatlimab
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingPhase 2The Netherlands Cancer InstituteNCT03026140Written as Relatlimab (BMS-986016)
- ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRecruitingPhase 2NYU Langone HealthNCT07504796Written as Relatlimab
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingPhase 2NYU Langone HealthNCT05428007Written as Nivolumab/Relatlimab
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaActive, not recruitingPhase 3Bristol-Myers SquibbNCT05625399Written as Nivolumab + Relatlimab
- PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaActive, not recruitingPhase 2Massachusetts General HospitalNCT05034536Written as Relatlimab
- Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer PatientsCompletedPhase 2University Hospital, EssenNCT04205552Written as Relatlimab 10 MG/ML Intravenous Solution
- REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric CancerActive, not recruitingPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03610711Written as Relatlimab
- An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedPhase 1/2Bristol-Myers SquibbNCT03459222Written as Relatlimab
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedPhase 2Bristol-Myers SquibbNCT02060188Written as BMS-986016
- T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedPhase 1/2Inge Marie SvaneNCT04611126Written as Relatlimab
- Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT02966548Written as Relatlimab
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1/2CelgeneNCT03310619Written as Relatlimab
- An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT02488759Written as Relatlimab
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesCompletedPhase 1/2Bristol-Myers SquibbNCT02061761Written as BMS-986016
As the comparator · 4 — what is tested is compared with relatlimab
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916Written as relatlimab+nivolumab
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as nivolumab plus relatlimab
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]RecruitingPhase 3Replimune, Inc.NCT06264180Written as Nivolumab + Relatlimab
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)RecruitingPhase 3Immunocore LtdNCT06112314Written as Nivolumab + Relatlimab
Codes
What other systems call relatlimab · ClinicalTrials.gg INT001801
- MeSH (NLM) C000721227relatlimabOne source ClinicalTrials.gov
- UNII (FDA) AF75XOF6W3RELATLIMABConfirmed FDA, Wikidata
- RxNorm 2596773One source FDA
- Wikidata Q58315670relatlimabConfirmed FDA, Wikidata
- NCI Thesaurus C111999RelatlimabOne source FDA
- DrugBank DB14851One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000721227 | relatlimab | One source ClinicalTrials.gov |
| UNII (FDA) | AF75XOF6W3 | RELATLIMAB | Confirmed FDA, Wikidata |
| RxNorm | 2596773 | — | One source FDA |
| Wikidata | Q58315670 | relatlimab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C111999 | Relatlimab | One source FDA |
| DrugBank | DB14851 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.